AdlyThebaudMD

Clinical Trials

• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) Start of enrollment: 2011 Feb 01

  Completed

  Phase 2, Phase 3

• Pediatric Schizophrenia Efficacy and Safety Study Start of enrollment: 2013 Aug 01

  Completed

  Phase 3

• Lurasidone Pediatric Autism Study Start of enrollment: 2013 Aug 01

  Completed

  Phase 3

• Pediatric Open-Label Extension Study Start of enrollment: 2013 Sep 30

  Completed

  Phase 3

• Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18

  Completed

  Phase 3

• A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting Start of enrollment: 2015 Aug 01

  Completed

  Phase 3

• Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Nov 19

  Completed

  Phase 3

• A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) Start of enrollment: 2016 Oct 29

  Active, not recruiting

• Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® Start of enrollment: 2014 Jun 01

  Terminated

  Phase 2, Phase 3

  Roles: Principal Investigator, Contact

• Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults Start of enrollment: 2023 Jan 31

  Recruiting

  Phase 3

  Roles: Contact

• A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder Start of enrollment: 2023 Aug 16

  Recruiting

  Phase 3

  Roles: Contact

• Join now to see all